000 06254cam a2200601Ma 4500
001 ocn958454824
003 OCoLC
005 20190328114816.0
006 m o d
007 cr |n|||||||||
008 160916s2016 xx ob 000 0 eng d
040 _aIDEBK
_beng
_epn
_cIDEBK
_dEBLCP
_dSTF
_dQCL
_dOCLCQ
_dIDEBK
_dFEM
_dIDB
_dOCLCQ
_dYDX
_dOPELS
_dN$T
_dGZM
_dOCLCO
_dOCLCQ
_dOCLCA
_dU3W
_dMERUC
_dOCLCO
_dD6H
_dCHVBK
_dOCLCQ
_dOCLCO
019 _a958864693
_a962435822
_a968097371
_a969078522
020 _a012811312X
_q(ebk)
020 _a9780128113127
020 _z0128113111
020 _z9780128113110
035 _a(OCoLC)958454824
_z(OCoLC)958864693
_z(OCoLC)962435822
_z(OCoLC)968097371
_z(OCoLC)969078522
050 4 _aRC123.C3
060 4 _aWC 470
072 7 _aHEA
_x039000
_2bisacsh
072 7 _aMED
_x014000
_2bisacsh
072 7 _aMED
_x022000
_2bisacsh
072 7 _aMED
_x112000
_2bisacsh
072 7 _aMED
_x045000
_2bisacsh
082 0 4 _a616.9/693061
_223
100 1 _aKumar, Awanish.
245 1 0 _aAnticandidal agents /
_h[electronic resource]
264 1 _a[Place of publication not identified] :
_bElsevier Science,
_c2016.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_2rda
588 0 _aPrint version record.
505 0 _aFront Cover; Anticandidal Agents; Copyright Page; Contents; List of Figures; List of Tables; 1 Introduction; Pathogenesis and Virulence; Genome and Proteome; Genetics; Metabolome; 2 Host-Pathogen Interaction; Morphogenesis; Immune Responses; Delayed-Type Hypersensitivity; Pattern Recognition Receptors; TH Cell Response; 3 Antifungals Used Against Candidiasis; Azoles; Activity and Mechanism of Action; Azole Variants and Their Structure; Ketoconazole; Itraconazole; Fluconazole; Voriconazole; Posoconazole; Ravuconazole; Terconazole; Other Notable Triazoles Include; Polyenes.
505 8 _aActivity and Mechanism of ActionStructure and Variants; Amphotericin B; Nystatin; Natamycin; Echinocandins; Activity and Mechanism of Action; Echinocandins Variants; Caspofungin; Micafungin; Anidulafungin; Pneumocandins; Echinocandin B; Cilofungin; Allylamines; Activity and Mechanism of Action; Variants of Allylamines; Terbinafine; Naftifine; Pyrimidines; Activity and Mechanism of Action; Pyrimidine Variants; 5-FC or Flucytosine; Thiocarbamates and Morpholines; Tolnaftate; Morpholines; Other Inhibitors; Cell Wall Synthesis Inhibitors; Chitin Biosynthesis Inhibitors.
505 8 _aErgosterol Biosynthesis InhibitorGlucan Synthesis Inhibitors; Novel Inhibitors; Expected Drugs (Compounds in Pipeline); SCY078; Ara-sertaconazole Nitrate; VT-1161; MGCD290; E1210; T-2307; ASP9726; Biafungin (CD101); Isavuconazole; Albaconazole; BQM-Bis [1, 6]quinolizinium 8-Methyl-Salt; Quinazolines; Indole and its Derivatives; Inhibitor Molecules; Sordarins; Tacrolimus; Ascomycin; Milbemycin; Unnarmicin A and Unnarmicin C; Verapamil; Disulfiram; Enniatin B; Trichostatin A; Levofloxacin and Derivatives; Differential Expression of Genes in Response to Drugs; 4 Drug Resistance in Candida.
505 8 _aEmergence of Drug ResistanceSpread of Drug Resistance; Persistence of Drug Resistance; International Data; National Data; Multidrug Resistance; 5 Multidrug Resistance and Transporters; Overview of Efflux Pumps; ABC Transporters; MFS Transporters; Fungal Efflux-Mediated Drug Resistance; Overcoming Efflux-Mediated Drug Resistance; 6 Potential Anticandidal Targets; Surface Targets; ABC Transporters; Key Factors; MFS Transporters; QDR; Cellular Targets; Cross Talk; 7 Drug Development Strategies; In Vitro Based; Biochemical Estimation; Toxicity Assay; Drug Susceptibility; Effects on Biofilm.
505 8 _aIn Vivo BasedBioavailability; Toxicity; ADME; Absorption and Distribution; Metabolism and Excretion; Pharmacokinetics and Pharmacodynamics; In Silico Based; Computer-Aided Drug Discovery and Development; Molecular Docking; Molecular Modeling; Virtual Screening; Quantitative Structured Activity Relationship; 8 Conclusion; Abbreviations; Bibliography; Back Cover.
520 _aAnticandidal Agents provides the latest information on candida drug resistance and its remedial implications. In this compilation, users will find a comprehensive view on overcoming resistance in anticandidal drugs, along with information on novel molecules. Candida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines. Lately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics. Presents a complete understanding of candida resistance to help in the development of therapeutic expansion and novel drugs Provides thorough information on candida drug resistance and its remedial implications Covers crucial mechanisms of resistance that will help develop strategies for overcoming the hindrance in current therapeutics.
504 _aIncludes bibliographical references.
650 0 _aCandidiasis
_xChemotherapy.
650 7 _aHEALTH & FITNESS
_xDiseases
_xGeneral.
_2bisacsh
650 7 _aMEDICAL
_xClinical Medicine.
_2bisacsh
650 7 _aMEDICAL
_xDiseases.
_2bisacsh
650 7 _aMEDICAL
_xEvidence-Based Medicine.
_2bisacsh
650 7 _aMEDICAL
_xInternal Medicine.
_2bisacsh
650 2 _aCandidiasis
_xtherapy.
655 4 _aElectronic books.
776 0 8 _iPrint version:
_aKumar, Awanish.
_tAnticandidal agents.
_dSan Diego, CA : Academic Press, [2016], �2017
_z9780128113110
_z0128113111
_w(OCoLC)953708342
856 4 0 _3ScienceDirect
_uhttp://www.sciencedirect.com/science/book/9780128113110
999 _c247422
_d247422